Show simple item record

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

dc.contributor.authorLiang, Barry J.
dc.contributor.authorPigula, Michael
dc.contributor.authorBaglo, Yan
dc.contributor.authorNajafali, Daniel
dc.contributor.authorHasan, Tayyaba
dc.contributor.authorHuang, Huang-Chiao
dc.date.accessioned2021-06-04T16:32:10Z
dc.date.available2021-06-04T16:32:10Z
dc.date.issued2020-01-02
dc.identifierhttps://doi.org/10.13016/ew3u-hnjm
dc.identifier.citationLiang, B.J., Pigula, M., Baglo, Y. et al. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting. J Nanobiotechnol 18, 1 (2020).en_US
dc.identifier.urihttp://hdl.handle.net/1903/27107
dc.description.abstractPhotoimmunotherapy involves targeted delivery of photosensitizers via an antibody conjugate (i.e., photoimmunoconjugate, PIC) followed by light activation for selective tumor killing. The trade-off between PIC selectivity and PIC uptake is a major drawback limiting the efficacy of photoimmunotherapy. Despite ample evidence showing that photoimmunotherapy is most effective when combined with chemotherapy, the design of nanocarriers to co-deliver PICs and chemotherapy drugs remains an unmet need. To overcome these challenges, we developed a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of three clinically used agents: anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab (Cet), benzoporphyrin derivative (BPD) photosensitizer, and irinotecan (IRI) chemotherapy.en_US
dc.description.urihttps://doi.org/10.1186/s12951-019-0560-5
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.subjectPhotoimmunoconjugateen_US
dc.subjectIrinotecan liposome injectionen_US
dc.subjectBenzoporphyrin derivativeen_US
dc.subjectEpidermal growth factor receptoren_US
dc.subjectMulti-drug deliveryen_US
dc.titleBreaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targetingen_US
dc.typeArticleen_US
dc.relation.isAvailableAtA. James Clark School of Engineeringen_us
dc.relation.isAvailableAtFischell Department of Bioengineeringen_us
dc.relation.isAvailableAtDigital Repository at the University of Marylanden_us
dc.relation.isAvailableAtUniversity of Maryland (College Park, MD)en_us


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record